A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Lifitegrast (Xiidra)

Xiidra ® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

First FDA approval2016-07-11
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$757.5M in CY2024 Part D spend731K claims · 281K beneficiaries · 329 plans surveyed

Lowest NADAC
$11.84/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$11.84
Across all dosage forms in distribution.
Highest NADAC
$11.84
Range is tight.
Plans with PA
42 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Lifitegrast used for?

Xiidra ® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Is there a generic for Lifitegrast?

No. Lifitegrast is brand-only with no generic equivalents currently in market.

How much does my plan pay for Lifitegrast?

Across 329 Part D plans, Lifitegrast averages $11.84/unit (NADAC). Lowest available: $11.84/unit. Highest in distribution: $11.84/unit.

Is Lifitegrast on the FDA shortage list?

No. Lifitegrast is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.